GSK plc (LSE/NYSE: GSK) today announced it has completed the acquisition of Affinivax, Inc (Affinivax), a clinical-stage biopharmaceutical company based in Cambridge (Boston, Massachusetts). Affinivax has pioneered the development of a novel class of vaccines, the most advanced of which are next-generation pneumococcal vaccines.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Affinivax, Inc. (“Affinivax”), a clinical stage biopharmaceutical company pioneering the development of a novel class of vaccines with its MAPS™ (Multiple Antigen Presenting System) platform, announced the company is presenting preclinical data demonstrating that a next generation pneumococcal vaccine candidate incorporating a novel pneumococcal fusion protein conferred enhanced protection in a highly virulent model of serotype 3 invasive pneumococcal disease, at the 12th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD-12) taking place on June 19-23 in Toronto.
GSK to spend up to $3.3 bln on Affinivax to boost vaccines roster
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Affinivax, Inc. (“Affinivax”), a clinical stage biopharmaceutical company pioneering the development of a novel class of vaccines with its MAPS™ (Multiple Antigen Presenting System) platform, today announced the company will present a poster highlighting COVID-19 MAPS™ vaccine non-human primate data at IMMUNOLOGY2022™, the annual meeting of the American Association of Immunologists (AAI) in Portland, Oregon (May 6-10, 2022).
CAMBRIDGE, Mass. & TOKYO--(BUSINESS WIRE)--Affinivax, Inc. (“Affinivax”) and Astellas Pharma Inc. (“Astellas”) today announced that they have entered into an agreement whereby Affinivax has reacquired the exclusive worldwide rights to ASP3772, a novel vaccine candidate targeting Streptococcus pneumoniae. In conjunction with the rights reacquisition by Affinivax, ASP3772 will be renamed AFX3772. Closing of the transaction is subject to clearance under the Hart-Scott Rodino Antitrust Improvements Act, which is expected in March or April of 2022. Under the terms of the parties’ new agreement, Astellas will receive a $65 million upfront payment and will be eligible to receive milestone payments and royalties tied to the clinical development and commercialization of ASP3772, as well as royalties tied to the commercialization of Affinivax’s next generation pneumococcal vaccine products designed to treat Streptococcus pneuomoniae.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Affinivax, Inc. (“Affinivax”), a clinical stage biopharmaceutical company pioneering the development of a novel class of vaccines with its MAPS™ (Multiple Antigen Presenting System) technology platform, today announced the appointment of Dr. Rick Malley as Chief Scientific Officer. He will also remain in his current position as the Kenneth McIntosh Chair in Pediatric Infectious Diseases at Boston Children’s Hospital. Dr. Malley is a highly regarded clinician and researcher with a long history of leadership in the field of infectious disease and pediatric medicine, most notably in his studies on the pathogenesis and prevention of bacterial and viral infections and his work developing novel vaccines against pneumococcus.
CEPI, the Coalition for Epidemic Preparedness Innovations, and Affinivax Inc. have announced a partnership to advance the development of a novel vaccine that could provide broad protection against SARS-CoV-2 variants, and potentially other betacoronaviruses.
OSLO, Norway & CAMBRIDGE, Mass.--(BUSINESS WIRE)--CEPI, the Coalition for Epidemic Preparedness Innovations, and Affinivax, Inc. (Affinivax) today announced a partnership to advance the development of a novel vaccine that could provide broad protection against SARS-CoV-2 variants, and potentially other betacoronaviruses.
Affinivax, Inc. (“Affinivax”), a clinical stage biopharmaceutical company pioneering the development of a novel class of vaccines with its MAPS™ (Multiple Antigen Presenting System) platform, today announced that Kara Bickham, MD, has joined the company as Chief Medical Officer. She brings a wealth of relevant experience across clinical practice, academic research and vaccine development, including her most recent role leading the clinical development of Vaxneuvance®, a 15-valent pneumococcal conjugate vaccine being developed by Merck & Co., Inc. for the prevention of Streptococcus pneumoniae in infants and children. Dr. Bickham will have an immediate impact on the development of Affinivax’s pneumococcal vaccine program – including its 24-valent vaccine currently in Phase 2 clinical trials and its next generation pneumococcal vaccine currently advancing toward clinical testing – as well as its pipeline of MAPS vaccine candidates targeting additional novel and resistant infectious diseases.
At the same time, Affinivax and Astellas revealed positive results from the Phase II trial of ASP3772